1. Cartexell

Cartexell

Cartexell, a subsidiary of Helixmith,
researches and develops CAR-T cell
therapies against solid tumor.

개인정보처리방침

닫기

이메일무단수집거부

닫기

CAR-T cells are developed by redesigning the T cells to actively find and destroy a specific part of cancer cells by inserting a chimeric antigen receptor(CAR) gene. This allows CAR-T cells to destroy the cancer cell while effectively, minimizing damage of normal cells.​

Conventional CAR-T has limitation in treating solid cancers. Cartexell developed a proprietary new CAR-T 2.0 technology, which controlls CAR-T cells and reinforce its anti-cancer activity. CAR-T 2.0 technology expresses a functional gene to block immune checkpoints, enhance infiltration of T cell, increase recruitment of immune cells or improve survival of T cell as well as CAR gene in T-cells concomitantly. ​

Cartexell possesses multiple CAR-T cell therapy candidates targeting solid tumors. ‘CX801’, the first product developed by Cartexell's research team, (currently owned by Helixmith) targets colorectal, ovarian, and prostate cancer, and ‘CX804’ targets neuroblastoma, ovarian and lung cancer. Cartexell is also developing CAR-T cell therapies targeting a diverse set of solid tumor antigens such as CX803 and CX805.​

Official Website of Cartexell

Target Disease & Strategy​

  1. Dendritic Cell
  2. T Cell
  3. Macrophage
  4. Natural Killer Cell
  5. Stromal Cell

Pipeline

  1. CX801

    Target TAG72
    • Indication

      Colorectal ovarian, prostate cancer

    • Status

      Technology transfer to US bluebird bio in 2015

  2. CX804

    Target : (Undisclosed)
    • Indication

      Neuroblastoma, ovarian, lung cancer

    • Status

      Preparing for IND application and clinical trial in 2022

  3. CX803

    Targets : (Undisclosed)
    • Indication

      Pancreatic, prostate, ovarian cancer, colorectal cancer

    • Status

      Preparing for IND application and clinical trial in 2023

  4. CX805

    Targets : (Undisclosed)
    • Indication

      Liver, gastric, lung cancer

    • Status

      Preparing for IND application and clinical trial in 2023

Development status​

Scroll

Indication Pre-clinical Phase 1 Phase 2 Phase 3
CAR-T CX801 Colorectal, Ovarian, Prostate Cancer
CX803 Pancreatic, Prostate, Ovarian, Colorectal Cancer
CX804 Neuroblastoma, Ovarian, Lung cancer 2022
CX805 Liver, Gastric, Lung Cancer